Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.59 |
| ▸ | NPC1 | O15118 | 6/20 | 0.59 |
| ▸ | RAB9A | P51151 | 6/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.59 |
| ▸ | TP53 | P04637 | 5/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.59 |
| ▸ | ESR1 | P03372 | 2/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.59 |
| ▸ | GFER | P55789 | 1/20 | 0.59 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.58 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.58 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2247467 | 0.90 | RAB9A (0.76) | HDAC6SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL25752031 | 0.90 | HDAC6 (0.55) | HDAC6SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL25498923 | 0.90 | SMN1; SMN2 (0.62) | HDAC6SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL2242768 | 0.90 | SMN1; SMN2 (0.63) | HDAC6SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL2245900 | 0.90 | NPC1 (0.76) | HDAC6SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL25625041 | 0.90 | HDAC6 (0.55) | HDAC6SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL9966868 | 0.89 | SMN1; SMN2 (0.66) | HDAC6SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL29407356 | 0.89 | SMN1; SMN2 (0.66) | HDAC6SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL17283310 | 0.89 | HDAC6 (0.59) | HDAC6SMN1; SMN2NPC1RAB9AKDM4E | |
| SCHEMBL9857519 | 0.89 | HDAC6 (0.57) | HDAC6SMN1; SMN2NPC1RAB9AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112119675-B | Organic electroluminescent element | 保土谷化学工业株式会社 | 2024-08-09 | — | — | CN | disclosed |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2022-11-10 | — | — | US | disclosed |
| US-20210226132-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT | HODOGAYA CHEMICAL CO., LTD. (JP) | 2021-07-22 | — | — | US | disclosed |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2021-07-06 | — | — | US | disclosed |
| EP-3826430-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT | Hodogaya Chemical Co., Ltd. (JP) | 2021-05-26 | — | — | EP | disclosed |
| CN-112119675-A | Organic electroluminescent element | 保土谷化学工业株式会社 | 2020-12-22 | — | — | CN | disclosed |
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2020-08-20 | — | — | US | disclosed |
| US-20190127365-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2019-05-02 | — | — | US | disclosed |
| US-20170008906-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20170008906-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2017-01-12 | — | — | US | disclosed |
| US-20150246917-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2015-09-03 | — | — | US | disclosed |
| US-9090661-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090661-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20140371138-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2014-12-18 | — | — | US | disclosed |
| US-20140371138-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2014-12-18 | — | — | US | disclosed |
| US-8871759-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871759-B2 | Inhibitors of hepatitis C virus replication | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP (NJ) | 2012-04-05 | — | — | US | disclosed |
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP (NJ) | 2012-04-05 | — | — | US | disclosed |
| WO-2010111483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | MERCK SHARP & DOHME CORP. (US) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262836-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | HDAC6 724/4885SMN1; SMN2 4833/4885NPC1 141/4885 |
| US-20120083483-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | HDAC6 724/4885SMN1; SMN2 4833/4885NPC1 141/4885 |
| US-20210226132-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT | SLC39A14, SLC39A7, SLC39A3 | HDAC6 1344/4885SMN1; SMN2 2461/4885NPC1 1687/4885 |
| US-20140371138-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | HDAC6 724/4885SMN1; SMN2 4833/4885NPC1 141/4885 |
| US-20170008906-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | HDAC6 724/4885SMN1; SMN2 4833/4885NPC1 141/4885 |
| US-20150246917-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | HDAC6 724/4885SMN1; SMN2 4833/4885NPC1 141/4885 |
| US-11053243-B2 | Inhibitors of hepatitis C virus replication | HAVCR2, HCCS, EIF2AK2 | HDAC6 724/4885SMN1; SMN2 4833/4885NPC1 141/4885 |
| US-20190127365-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | HDAC6 724/4885SMN1; SMN2 4833/4885NPC1 141/4885 |
| US-20220356182-A1 | INHIBITORS OF HEPATITIS C VIRUS REPLICATION | HAVCR2, HCCS, EIF2AK2 | HDAC6 724/4885SMN1; SMN2 4833/4885NPC1 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.